FISH, MDS/Myeloid Panel, -5/5q-, -7/7q-, +8, 20q-

Test Code

19799

CPT Codes
88275 (x3), 88271 (x6)

Includes

Methodology: Four probe sets associated with myelodysplastic syndrome (MDS) are included in this panel: -5/5q-, -7/7q-, +8, 20q-. 100-300 interphase nuclei are scored for each probe set to detect gain, loss, or rearrangements of the probe regions.

Preferred Specimen

5 mL whole blood or 3 mL bone marrow collected in sodium heparin (green-top) tube

Minimum Volume

1 mL whole blood or bone marrow

Other Acceptable Specimens

Whole blood or bone marrow collected in: Sodium heparin (royal blue-top) or sodium heparin lead-free (tan-top) tube

Instructions

Clinical history/reason for referral is required with test order. Prior therapy and transplant history should be provided.

Submit 3-5 mL whole blood or 1-3 mL bone marrow collected in a sodium heparin tube.
Specimen viability decreases during transit. Send specimen to testing laboratory for viability determination. Do not freeze. Do not reject.

Transport Temperature

Room temperature

Specimen Stability

Room temperature: See instructions
Refrigerated: See instructins
Frozen: See instructions

Methodology
Fluorescence in situ Hybridization (FISH)

FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

Setup Schedule

Set up: Sun-Fri; Report available: 7 days

Reference Range

See Laboratory Report

Clinical Significance

Prognostic investigation in patients with myelodysplasia or other myeloid malignancies. Among the patients with myelodysplastic syndromes (MDS), 45-50% have a least one chromosome rearrangement, the most common of which can be detected using this fluorescence in situ hydridization (FISH) panel (-5/5q-,-7/7q-,+8,20q-). This panel of FISH probes can increase the detection rate of chromosome abnormalities at diagnosis and aid in follow-up testing for clinically significant chromosome abnormalities in MDS. The identification of the specific chromosome regions involved in a patient's disease may play a significant role in treatment decisions as MDS targeted therapies are developed.

Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.